Alumis (NASDAQ:ALMS) Given New $9.00 Price Target at HC Wainwright

Alumis (NASDAQ:ALMS) had its price target lowered by HC Wainwright from $15.00 to $9.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also issued reports on ALMS. Weiss Ratings lowered shares of Alumis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. Citigroup restated an “overweight” rating on shares of Alumis in a research report on Tuesday, September 1st. Oppenheimer reduced their price objective on shares of Alumis from $55.00 to $37.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 2nd. Robert W. Baird set a $27.00 price objective on shares of Alumis in a research report on Tuesday, September 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Wednesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.09.

Alumis Stock Performance

Shares of ALMS opened at $5.60 on Friday. The business has a 50-day moving average of $7.24 and a 200-day moving average of $20.46. Alumis has a 1 year low of $4.60 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.03. Alumis had a negative return on equity of 86.62% and a negative net margin of 5,844.54%. The business had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $1.90 million. Sell-side analysts predict that Alumis will post -2.95 EPS for the current fiscal year.

Insider Activity

In other Alumis news, Director Srinivas Akkaraju bought 546,581 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were bought at an average price of $10.63 per share, for a total transaction of $5,810,156.03. Following the transaction, the director directly owned 4,937,026 shares in the company, valued at approximately $52,480,586.38. This trade represents a 12.45% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders sold 99,754 shares of company stock valued at $1,037,804. 33.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Alumis

A number of hedge funds have recently added to or reduced their stakes in ALMS. Integrated Wealth Concepts LLC acquired a new stake in shares of Alumis in the 2nd quarter valued at about $33,000. KBC Group NV bought a new stake in Alumis in the 1st quarter valued at about $42,000. State of Wyoming acquired a new position in Alumis during the 1st quarter worth approximately $57,000. Dimensional Fund Advisors LP raised its stake in Alumis by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 23,115 shares of the company’s stock worth $509,000 after buying an additional 2,599 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in Alumis by 600.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock worth $69,000 after buying an additional 2,684 shares during the period.

Alumis News Summary

Investors following ALMS have been watching these news items:

• Positive Sentiment: Alumis reported new Phase 3 data showing rapid, durable improvements in plaque psoriasis. The company said envudeucitinib had the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies, reinforcing its potential clinical differentiation. Alumis Q3 2026 financial results and business updates
• Neutral Sentiment: Q3 adjusted performance was slightly better than expected: the loss was $0.73 per share versus the $0.76 consensus, while revenue of $1.91 million was essentially in line with estimates of $1.90 million. The small beat is tempered by continued losses. Alumis earnings results
• Negative Sentiment: Wells Fargo cut its price target to $18 from $25, and HC Wainwright lowered its target to $9 from $15. Both firms kept bullish ratings—Overweight and Buy, respectively—but the reductions may signal more cautious expectations and pressure the stock. Wells Fargo price target report

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.